FEMASYS INC

Femasys Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement for continued listing. The company received formal notice from Nasdaq on June 23, 2026, confirming that the matter is now closed. This follows a 1-for-20 reverse stock split on June 5, 2026, after which the stock maintained a bid price of $1.00 or more for 10 consecutive business days. CEO Kathy Lee-Sepsick stated that regaining compliance is an important development for Femasys and its shareholders, allowing the company to focus on advancing its strategic priorities.

Femasys Inc. announced it has regained compliance with The Nasdaq Stock Market LLC's Listing Rule 5550(a)(2), the minimum bid price requirement, and that the matter is now closed. CEO Kathy Lee-Sepsick highlighted this as an important development for the company and its shareholders, allowing them to focus on strategic priorities and expanding access to innovative reproductive health solutions. Femasys continues to advance its fertility products like FemaSeed® and its FemBloc® permanent birth control, which received European, UK, and New Zealand regulatory approvals in 2025, with a U.S. FDA pivotal trial ongoing.

Femasys Inc. filed a Certificate of Amendment on June 5, 2026, to effect a 1-for-20 reverse stock split of its outstanding common stock, which became effective at 8:40 a.m. Eastern Time on the same day. This action, authorized by stockholders on April 29, 2026, combines every 20 shares into one without changing the par value. Proportionate adjustments will be made to equity awards and shares reserved under equity compensation plans, with fractional shares rounded up. The company's common stock will commence trading on The Nasdaq Capital Market on a split-adjusted basis on June 8, 2026.

Femasys Inc. announced a 1-for-20 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on June 5, 2026. The company's common stock will begin trading on a split-adjusted basis with the market open on June 8, 2026, under its existing trading symbol "FEMY." Each 20 pre-split shares will convert into one new share, with fractional shares rounded up to the next whole share.

Femasys Inc. released an updated investor presentation detailing its multi-asset women's reproductive health portfolio, including fertility treatments and permanent birth control solutions. The presentation highlights market-first solutions like FemaSeed for fertility and FemBloc for non-surgical permanent birth control, emphasizing their potential for significant revenue growth and expanded patient access. The company outlined strategic execution points for 2026, focusing on product launches, partnerships, and clinical trial advancements.

Femasys Inc. announced it has received CE Mark approval for its FemHSG™ Catheter, which will further expand the company's product portfolio in Europe through commercial partners. The FemHSG Catheter, designed for use with the FemVue device, supports efficient in-office ultrasound-based evaluation during the initial fertility workup. This approval is expected to improve access to timely and affordable fertility diagnosis and intervention for women worldwide, strengthening Femasys' growing fertility offerings.

Femasys Inc. reported a net income of $846,100 for the first quarter of 2026, a substantial improvement compared to a net loss of $(5,896,839) in the same period last year. This income was significantly influenced by non-operating gains from changes in the fair value of conversion option and warrants liabilities. Sales for the quarter increased to $424,889. Despite the reported net income, the company's cash and cash equivalents decreased to $5,386,041, and management expressed substantial doubt about its ability to continue as a going concern due to an accumulated deficit and expected future operating losses.

Femasys Inc. announced its financial results for the first quarter ended March 31, 2026, reporting a significant turnaround with a net income of $846,100, compared to a net loss of $5.9 million in the prior year. Sales increased by 24.5% to $424,889, primarily driven by FemBloc sales, while R&D expenses decreased by 55.9%. The company also provided a corporate update highlighting the commercial adoption of FemaSeed Complete, initiation of the FemBloc FINALE pivotal clinical trial, and expansion into international markets through strategic partnerships.

Femasys Inc. reported a net income of $846,100 for Q1 2026, a significant improvement from a net loss of $5.9 million in the prior year, with sales increasing 24.5% to $424,889. The company made substantial clinical, regulatory, and commercial progress, including initiating patient enrollment in the FINALE pivotal trial for FemBloc® and receiving AMA CPT code approval for FemaSeed®. Strategic partnerships were established to expand international market access and commercialization. Femasys expects its current cash resources of $5.4 million to fund operations into Q3 2026.

Femasys Inc. will hold its 2026 Annual Meeting of Stockholders on June 24, 2026, at its Suwanee, Georgia offices. Stockholders will vote on the election of two Class II directors and the ratification of KPMG LLP as the independent auditor for fiscal year 2026. The record date for voting is April 27, 2026, with 60,390,686 shares outstanding. The company also detailed its corporate governance practices, including director independence and a compensation clawback policy.